What are your thoughts on reporting CPT code 64590 when placing an eCoin device?
eCoin is a new technology for the management of bladder overactivity that is implanted near the posterior tibial nerve subcutaneously.
How to understand Medicare from the patient perspective
Here is what patients experience enrolling in and participating in Medicare.
What physicians should know about apologizing to patients
Apology laws limit the admissibility of apologetic statements.
Consider financial toxicity when recommending novel hormonal therapies for prostate cancer
"Ultimately, it will be the treating physician’s responsibility to identify cost-effective alternatives and available resources to help mitigate the financial toxicity incurred from novel cancer therapies," writes Badar M. Mian, MD.
Pushing past the pandemic’s impact on prostate cancer screening
"Cancer doesn’t take a holiday or vacation, and it doesn’t care about a pandemic. Our efforts to reduce deaths from prostate cancer through screening and early detection must continue," writes Michael S. Cookson, MD, MMHC.
Botox, sacral nerve stimulation highlighted as emerging OAB treatments for elderly patients
Two studies shared at the 2022 Annual Meeting of the South Central Section of the AUA highlighted onabotulinumtoxinA and sacral nerve stimulation as alternative treatment options for patients older than 70 years with overactive bladder.
Diversity in Urology: Progress made, but there is more work to be done
Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Trial launches of imaging agent for PSMA-negative prostate cancer patients
The target of 64Cu SAR-Bombesin is the Gastrin Releasing Peptide receptor, which is found on prostate tumors as well as several other tumors.
Long-term data support MRI-guided TULSA for localized prostate cancer
"The biggest advantage of this technique is that because the sound waves are coming from inside and going outwards, it doesn't destroy anything beyond the prostate, at least in theory,” said Michael Koch, MD.
Artificial urinary sphincter: 50 years of evolution and positive outcomes
In this interview, Andrew C. Peterson, MD, MPH, discusses the development of the artificial urinary sphincter.
What do you tell your patients about all the new erectile dysfunction treatments being advertised to the public?
“Community urologists need to interact more intimately with academic urologists so all of us have a voice in this direct-to-consumer conversation," says 1 urologist.
EU OKs novel biomarker and machine learning–powered test for prostate cancer
The ClarityDX Prostate test assesses a combination of clinical and biological biomarker data and provides a risk score that a patient biopsy would show a clinically significant prostate cancer.
FDA accepts application for N-803 in NMIBC
The application is supported by findings from the phase 2/3 QUILT-3.032 trial.
2 Clarke Drive Cranbury, NJ 08512